help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasprzycka, M.
Right arrow Articles by Wasik, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasprzycka, M.
Right arrow Articles by Wasik, M. A.
(American Journal of Pathology. 2006;168:1631-1641.)
© 2006 American Society for Investigative Pathology

Expression and Oncogenic Role of Brk (PTK6/Sik) Protein Tyrosine Kinase in Lymphocytes

Monika Kasprzycka*{dagger}, Miroslaw Majewski*{ddagger}, Zhi-Jong Wang*, Andrzej Ptasznik§, Maria Wysocka, Qian Zhang*, Michal Marzec*, Phyllis Gimotty||, Mark R. Crompton** and Mariusz A. Wasik*

From the Departments of Pathology and Laboratory Medicine,* Medicine,§ Dermatology, and Biostatistics and Epidemiology,|| University of Pennsylvania, Philadelphia, Pennsylvania; the Department of Clinical Immunology,{dagger} Warsaw Medical University, Warsaw, Poland; the Department of Hematology,{ddagger} Institute of Hematology and Blood Transfusion, Warsaw, Poland; and the School of Biological Sciences,** Royal Holloway University of London, Surrey, United Kingdom

Tyrosine kinases play a fundamental role in cell proliferation, survival, adhesion, and motility and have also been shown to mediate malignant cell transformation. Here we describe constitutive expression of the protein tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and B-cell populations. The kinase is expressed in the nuclear localization and activated state. Brk expression was also induced in normal T cells on their activation. Introduced expression of the Brk gene resulted in markedly diminished cytokine and growth factor dependence of transfected BaF3 lymphocytes in regard to their in vitro proliferation and survival. Brk also conferred in vivo oncogenicity on the BaF3 cells. siRNA-mediated inhibition of the endogenous Brk in malignant T cells diminished their growth and survival capacity. These findings document inducible expression of Brk in normal T lymphocytes and persistent expression of the activated kinase in malignant T and B cells. Furthermore, our results indicate that Brk may play a key role in lymphomagenesis, hence identifying the kinase as a potential therapeutic target in lymphomas.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
C.-H. Shen, H.-Y. Chen, M.-S. Lin, F.-Y. Li, C.-C. Chang, M.-L. Kuo, J. Settleman, and R.-H. Chen
Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion
Cancer Res., October 1, 2008; 68(19): 7779 - 7787.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology.